Genmab — December 2022

Bulder

Seems like a little concern over the fatal infections in the tec-dara-len combo. One covid and one sepsis. Hope this will be discussed on R&D Day.

Bulder

https://www.youtube.com/watch?v=8yirKYro2cw talquetamab

ProinvestorNEWS

Just a moment...

(www.proinvestor.com)

GeorgeBest

@Bulder. Jan will probably say it is a Janssen product, and refer the analyst to them.

Bulder

Also talq had 2 deaths due to covid. Maybe this problem will be solved when covid is over.

Bulder

GB: I think they should discuss the general issue with risk of infections and bispecifics.

E_L

at the same time, according to Dr Chari: “If you measure Covid antibodies, patients on [talquetamab] are producing antibodies. That’s a really different signal than what we’ve seen before.”

Bulder

Ye s, but as he says, it is tragic to loose a cr- patient to covid. I would like to hear if they can come up with something to avoid infections.

Bulder

Does anybody know when hex38 will be presented.

E_L

tonight https://ash.confex.com/ash/2022/webprogram/Paper159116.html

E_L

but it is a poster, so you have to hope someone will post something on twitter, we'll probably have to wait for the R&D

E_L

rest of the schedule by the way: https://ir.genmab.com/news-releases/news-release-details/genmab-announces-multiple-abstracts-be-presented-64th-annual

ProinvestorNEWS

ASH tråd. Fyld gerne på: https://www.proinvestor.com/boards/108608/

Solsen

Rafineret teknologi viser gode resultater. Dejligt med de mange fremskridt i cancerbehandling https://www.bbc.com/news/health-63859184

Bulder

Ham her har visse indvendinger imod talq-studiet: https://www.youtube.com/watch?v=PAvLpjVstOk

Helge_LarsenPI-redaktør

Den første del af kritikken er svært for lægmand at vurdere. Håber at nogen af vore eksperter kan byde ind. Det med det uetiske med den homøopatiske dosering i lavdosisgruppen er til gengæld nemt for de fleste at forstå og være enig i. Det er jeg i hvert fald.

Bulder

Han er i hvert fald ikke begejstret for car-t. Og så peger han også på bivirkninger. Infektioner af tec og udslet på huden af talq. Men som han selv siger, der er en pris at betale. Om man skulle gå direkte til randomiserede studier fra fase 1, kan jeg ikke vurdere. Men hvis det var muligt, ville fda vel have krævet det.

peter12

Prasad er vist en lidt kontroversiel person https://tuftsdaily.com/news/2022/03/08/controversial-oncologist-dr-vinay-prasad-disavowed-by-dean-lectures-to-gsbs/

GeorgeBest

Epcoritamab+RDHAX/C: quickly effective and well tolerated in rrDLBCL in the EPCORE NHL-2 study https://twitter.com/amniebla/status/1601982162168954882?s=61&t=xIDx9wxi6oZSGwmTiFu4wQ

GeorgeBest

Epcoritamab CD20×CD3 with DHAX, n=29, 66% primary refractory, 21 pts responded and 16 proceeded to AutoSCT, ORR 85%, 67% CR https://twitter.com/abhinav_deol/status/1601981658252836866?s=61&t=xIDx9wxi6oZSGwmTiFu4wQ